Celator's delivery platform results in FDA's fast-track designation for its cancer candidate

Celator Pharmaceuticals received fast-track designation for its candidate for the treatment of secondary acute myeloid leukemia in elderly patients. CPX-351 is designed to achieve sustained release of the anticancer drugs cytarabine and daunorubicin in a precise ratio.

U. Arizona team looks to bring GI delivery vehicle to market

Researchers have developed and are looking to commercialize a drug delivery system designed to treat inflammation and ulcerations in the colon. The "molecular truck" delivers the drug 5-aminosalicylic acid to the colon, where it can treat diseases such as ulcerative colitis and Crohn's.

'Micromotors' made of zinc and polymer actively release drugs at stomach lining

Tiny polymer tubes coated with zinc may one day be able to treat stomach conditions such as ulcers by acting as "micromotors" carrying drugs to the stomach lining. Animal studies at the University of California, San Diego, demonstrated in vivo that the synthetic motors enhanced the efficiency of drug delivery to the stomach.

India's Piramal to buy U.S. maker of sterile injectables, antibody drug conjugates

India's Piramal Enterprises made official its intention to purchase Kentucky's Coldstream Laboratories, for $30.6 million, a move that will push the company further into the contract manufacturing of drug delivery components like sterile injectable products, lyophilized (freeze-dried) parenterals, and antibody drug conjugates.

BD must still pay $350M+ due to safety syringe spat; other punishments delayed pending appeal

A federal court has upheld the $350 million-plus in damages that Becton Dickinson owes Retractactable Technologies due to a legal spat over drug-delivering prefilled syringes. But the court stayed a previous order requiring the company to inform end users about its false advertising regarding the syringes.

Intersect ENT announces prelim Q4 financials at JPM, defining goals for its drug-loaded stents

Sinusitis implant maker Intersect ENT took the stage at the JP Morgan Healthcare Conference in San Francisco this week to announce preliminary financial results from the fourth quarter of 2014, its first full quarter since its July IPO worth $63.3 million.

Tekmira stock soars on acquisition of OnCore to strengthen hep B pipeline

RNAi specialist Tekmira Pharmaceuticals expanded its reach with the announcement of the purchase of OnCore Biopharma, developer of an all-oral candidate for hepatitis B, saying that a combination therapy approach is the optimal way to treat that disease.

Pill-maker Capsugel collects Australian uni's tech for greater bioavailability

New Jersey capsule technology specialist Capsugel has picked up a drug delivery platform developed at Australia's Monash University that makes use of lipidlike counter-ion salts to improve the bioavailability of certain drugs.

Extended-release drugs to face extra scrutiny from FDA's new Office of Pharmaceutical Quality

"Modified release is a high-risk area, so we're going to put a lot of emphasis on it," said the deputy director of the FDA's new Office of Pharmaceutical Quality, Lawrence Yu, during a press conference describing the new division.

Alnylam and Isis strengthen RNAi alliance, agree to swap IP

Alnylam and Isis Pharmaceuticals announced an intellectual property cross-licensing agreement that they hope will leave them both better equipped to deal with the challenges of developing the first commercial RNAi therapy, including utilization of the promising but still-unproven RNA interference drug delivery pathway, and sometimes jittery investors.

FDA approves AbbVie's Parkinson's drug, featuring delivery straight into the GI tract

The FDA just approved AbbVie's novel formulation of the standard Parkinson's drugs carbidopa and levodopa, Duopa, which is delivered straight into the patient's small intestine over 16 consecutive hours using an infusion pump and procedurally placed tube.

Palo Alto pain management startup Carbylan vies for $86M IPO

Biotech startup Carbylan Therapeutics is looking to raise $86 million in an IPO to support its injectable osteoarthritis pain treatment, which is currently in Phase III with another late-stage trial on the way in mid-2015.

Blend Therapeutics receives $21M in Series B round

Blend Therapeutics announced that it has received $21 million in new financing via a Series B venture round, as well as debt financing from an institutional investment firm to advance its Pentarin biologic drug conjugates.

Australia's EnGeneIC receives $10M in Series B round for studies of anticancer delivery tech

Australia's EnGeneIC announced the completion of a $10 million Series B round for its antibody-targeted EDV nanocell technology platform for cancer drug delivery, led by Boston's GRT Capital Partners.

Graphene 'flying carpet' strips deliver two cancer drugs, each to a different cell target

Researchers have developed graphene strips that have demonstrated the ability to carry two different cancer drugs and target each to the part of the cell where it will be most effective. The surface area of a flat strip in particular suits these particles to the delivery of the cancer drugs TRAIL and doxorubicin.

NeuroDerm's subcutaneously delivered alternative to oral levodopa shows promise in Parkinson's trial

Investors were thrilled by the Phase IIa clinical trial results of Neuroderm's continuously delivered Parkinson's candidates that are administered via a belt or patch pump, offering patients an alternative to traditional orally delivered levodopa, which is notorious for its fluctuating concentrations in the blood.

After 5-year delay, FDA approves Hospira's injectable painkiller

With FDA approval now in hand, Dyloject, an injectable nonsteroidal anti-inflammatory drug, could fill the void left by the expiration of most of the patents protecting Hospira's sedative, Precedex, which accounted for around 11% of the company's annual sales of $4 billion in mid-2014.

Cytosorbents no longer an OTC stock, uplists to Nasdaq

Starting today, CytoSorbents, maker of the CytoSorb extracorporeal cytokine adsorber to reduce inflammation in critically ill and cardiac surgery patients, will begin trading on the Nasdaq Capital Market instead of the over-the-counter market.

Gelatin-based nanoparticles enter brain to treat stroke in crucial time window

South Korean researchers at the University of Illinois Urbana-Champaign have developed a delivery technique that uses bits of gelatin to encapsulate drugs and carry them to the brain without surgery. The method shows promise for stroke patients, extending the window during which treatment can be effective.

Platform success leads to NDA for Endo, BioDelivery inside-the-cheek pain drug

Squeezing it in at the end of the year, Endo Pharmaceuticals and BioDelivery Sciences filed an NDA with the FDA for the companies' buccal Buprenorphine painkiller.